Daiichi Sankyo and MSD for the DXd antibody-drug conjugate candidates, patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan Intas Pharmaceuticals and Henlius Biotech for the commercialization of serplulimab (Hetronifly) in Europe and India ...
(CAR-T) cell therapies Daiichi Sankyo and MSD for the DXd antibody-drug conjugate candidates, patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan Intas Pharmaceuticals and Henlius Biotech for the commercialization of serplulimab (Hetronifly) in Europe and India Johnson...